Replies to post #87022 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Yes, dosages were not quantified sufficiently in P2a - neither were AZ subtypes.

This is what the P2b will do based on the analysis of the P2a and extensions by Ariana and continued with the 300+ sample. Since the safety profile isn't an issue, I expect the FDA to permit further refinement of dosage and study after approval.

After all, 2-73 allows them to commute a death sentence for millions of people around the world. In the beginning, 6 months or 6 years won't matter with improved quality of life over SOC.

[powerwalker]

Tom, the new drug of Biogen and Ionis, Spinraza, was granted approval with ~20 positive responses out of the 120+ who were in the trial or less than 20%.

So if 2-73 is working for 25 out of 25, or 100%, why wouldn't/couldn't the FDA look positively on it, especially given the safety aspects of 2-73?